Fibrinolytic efficacy of amediplase, tenecteplase and scu-PA in different external plasma clot lysis models

Thrombosis and Haemostasis

Volumn 96, Issue 3, 2006, Pages 325-330

  Guimarães, Ana H C ^a   Barrett Bergshoef, Marrie M ^b   Criscuoli, Marco ^c   Evangelista, Stefano ^c   Rijken, Dingeman C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c Menarini Ricerche SpA   (Italy)

Author keywords

Amediplase; Fibrinolysis; Plasminogen activator; TAFI; Tenecteplase; Thrombolysis

Indexed keywords

AMEDIPLASE; CARBOXYPEPTIDASE; PLASMINOGEN ACTIVATOR; PROUROKINASE; TENECTEPLASE; THROMBOMODULIN;

ARTICLE; BLOOD CLOT LYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARBOXYPEPTIDASE U; CARBOXYPEPTIDASES; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; SENSITIVITY AND SPECIFICITY; SOLANUM TUBEROSUM; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 33748589984     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-04-0197     Document Type: Article

References (31)

1. Collen D. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 1987; 33: 77-86.
2. Dunn CJ, Goa KL. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovasc: Drugs 2001; 1: 51-66.
3. Stewart RJ, Fredenburgh JC, Leslie BA, et al. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem 2000; 275: 10112-20.
4. Colucci M, Cavallo LG, Agnelli G, et al. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Thromb Haemost 1993; 69: 466-72.
5. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-41.
6. Verheijen JH, Caspers MP Chang GT, et al. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525-30.
7. van Zonneveld AJ, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J Biol Chem 1986; 261: 14214-8.
8. Wijngaards G, Rijken DC, van Wezel AL, et al. Characterization and fibrin-binding properties of different molecular forms of pro-urokinase from a monkey kidney cell culture. Thromb Res 1986; 42: 749-60.
9. Rijken DC, Barrett-Bergshoeff MM, Jie AF, et al. Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2 tu-PA). Thromb Haemost 2004; 91: 52-60.
10. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-9.
11. de Munk GA, Groeneveld E, Rijken DC. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. J Clin Invest 1991; 88: 1680-4.
12. Doggrell SA. Amediplase. Menarini. Curr Opin Investig Drugs 2004; 5: 344-7.
13. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995; 92: 1883-90.
14. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996; 271:2133-8.
15. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
16. Bajzar L, Nesheim M, Morser J, et al. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2792-8.
17. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
18. Guimarães AHC, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Thromb Haemost 2004; 91: 473-9.
19. Nauland U, Rijken DC. Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C). Eur J Biochem 1994; 223:497-501.
20. Wu C, Dong N, da Cunha V, Martin-McNulty B, et al. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost 2003; 90: 414-21.
21. Astrup T, Brakman P, Nissen U. The estimation of fibrinogen. A revision. Scand J Clin Lab Invest 1965; 17: 57-65.
22. Leurs J, Wissing BM, Nerme V, et al. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-71.
23. Cruden NL, Lawes L, Masson P, et al. Inhibition of thrombin activatable fibrinolysis inhibitor augments fibrinolysis in human whole blood. J Thromb Haemost 2005; 3: 2351-3.
24. Colucci M, D'Aprile AM, Italia A, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 2001; 85: 661-6.
25. Nagashima M, Werner M, Wang M, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-42.
26. Mutch NJ, Moore NR, Wang E, et al. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 1: 2000-7.
27. Marx PF, Dawson PE, Bouma BN, et al. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 6688-96.
28. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29: 4-11.
29. Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002; 41: 1229-45.
30. Modi NB, Fox NL, Clow FW, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000; 40: 508-15.
31. Charbonnier B, Pluta W, De Ferrari G, et al. Evaluation of Two Weight-Adjusted Single Bolus of Amediplase to Patients with Acute Myocardial Infarction: The 3K2 Trial. Circulation 2001; 104: 538.